| Name | Title | Contact Details |
|---|---|---|
Patrick Baumhof |
Senior Vice President of Technology | Profile |
Mariola Fotin-Mleczek |
Chief Technology Officer | Profile |
Mariola Fotin-Mleczek |
Chief Technology Officer | Profile |
Introducing the most advanced platform for clinical genomic analysis… Solutions for each type of medical use Using data and machine learning to build a more accurate picture of each patient We are passionate about creating bioinformatic solutions that ...
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.
Ohana is pioneering a new frontier in reproductive medicine. Built upon a world-leading understanding of sperm biology, Ohana has created a best-in-class proprietary platform with broad applications across reproductive medicine.